





Yale Innovation Summit 2021

Interleukin-18: Powerful in a test tube, but a dud in the clinic




High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

By Michael B. Atkins, Michael T. Lotze, Janice P. Dutcher, Richard I. Fisher, Geoffrey Weiss, Kim Margolin, Jeff Abrams, Mario Sznol, David Parkinson, Michael Hawkins, Carolyn Paradise, Lori Kunkel, and Steven A. Rosenberg



Interleukin-18: Powerful in a test tube, but a dud in the clinic





A Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma


Ahmad A. Tahrini, MD¹, Michael Millward, MD², Paul Mainwaring, MD³, Richard Kefferd, MD⁴, Ted Logan, MD⁵, Anna Pavlick, MD⁶, Steven J. Kathman, MD⁷, Kevin H. Laubscher, MD⁸, Mohammed M. Dar, MD⁹, and John M. Kirkwood, MD¹

“Among 63 subjects evaluable for response, [only] 1 achieved a partial response... Due to the low apparent level of clinical efficacy, the study was terminated at the end of stage 1.”

IL-18 is restricted in tumors by an ultra high-affinity receptor decoy





Robertson et al., Clinical Cancer Research, 2008



Zhou et al., Nature, 2020

Decoy-Resistant IL-18 (DR-18)



Article

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Translating DR-18 into the clinic:

Phase I trial of lead DR-18 variant ST-067 to begin in Summer 2021


Yale spinout re-engineers an immunotherapy GSK, others once abandoned



Jason Mast
Associate Editor

Simcha debuts with \$25M to advance custom-built IL-18 for cancer

by Amirah Al Idrus | Jun 24, 2020 11:00am



Its lead program is a custom-built IL-18 that surmounts a hurdle faced by the native protein: a "decoy" IL-18 receptor that stops the drug from doing its job. (Shutterstock)

BIOTECH

STAT+

Engineering a better immunotherapy to outwit cancer — and launch a biotech

By ELIZABETH COONEY @cooney_liz / JUNE 24, 2020

Reprints

